Serological Markers of Clinical Improvement in MuSK Myasthenia Gravis
Our data support the quantification of MuSK antibodies by flow cytometry. Through a multimodal investigational approach, we showed that total MuSK-IgG levels, MuSK-IgG4 and MuSK-IgG2 levels, and MuSK-IgG affinity may represent promising biomarkers of disease outcomes in MuSK-MG.
Authors
- Gregorio Spagni (ORCID: https://orcid.org/0000-0003-0656-9671)
- Leslie Jacobson
- Valentina Damato (ORCID: https://orcid.org/0000-0003-1740-4522)
- Angela Vincent (ORCID: https://orcid.org/0000-0003-2395-8695)
- Silvia Falso (ORCID: https://orcid.org/0000-0002-6264-5299)
- Bo Sun (ORCID: https://orcid.org/0000-0002-5507-6657)
- Sean R. A. Devenish (ORCID: https://orcid.org/0000-0003-0607-8717)
- Amelia Evoli (ORCID: https://orcid.org/0000-0002-4644-2299)
Institutions
- German Center for Neurodegenerative Diseases (DE)
Publication Details
- Journal
- Neurology Neuroimmunology & Neuroinflammation
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1212/nxi.0000000000200313
- Citations
- 9
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 3.32
Funders
- Rare Diseases Clinical Research Network
- National Institute for Health and Care Research
- British Medical Association
- Ministero della Salute
- European Academy of Neurology
- National Institutes of Health